The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.
Artificial intelligence models are being tested for periodontal disease detection using intraoral photographs, but external validation shows performance often declines across populations and imaging devices.